Cargando…
SAT-LB073 SJX-653, a Novel Selective NK3 Antagonist, Demonstrates Activity on Pharmacodynamic Markers of NK3 Target Engagement
Background: NK3 antagonism is a clinically validated mechanism of action for treating menopausal vasomotor symptoms (“hot flashes”). In men, reductions of LH and T are sensitive pharmacodynamic markers of central NK3 antagonism, due to the known inhibitory effect of NK3 antagonists on GnRH pulsatili...
Autores principales: | Cormier, Jennifer, Boyce, Malcolm, van den Berg, Frans, Grau, Daniel, Turnquist, David, Corzo, Deya, Graham, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552009/ http://dx.doi.org/10.1210/js.2019-SAT-LB073 |
Ejemplares similares
-
Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men
por: Anderson, Richard A, et al.
Publicado: (2020) -
SUN-LB073 Giant Prolactinomas: Recidive (Case Report)
por: Galesanu, Corina
Publicado: (2019) -
MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission
por: Martel, Luciana, et al.
Publicado: (2019) -
SAT-LB083 Pituitary Apoplexy: What a Headache!
por: Perez Garcia, Yanet, et al.
Publicado: (2019) -
SAT-LB46 Depression as an Atypical Presentation of Cushing’s Disease
por: Pahwa, Dhivya, et al.
Publicado: (2020)